AELIS Stock Overview
A clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aelis Farma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.80 |
| 52 Week High | €13.60 |
| 52 Week Low | €2.80 |
| Beta | 0.21 |
| 11 Month Change | -22.22% |
| 3 Month Change | -75.86% |
| 1 Year Change | -79.10% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.78% |
Recent News & Updates
Take Care Before Jumping Onto Aelis Farma SA (EPA:AELIS) Even Though It's 29% Cheaper
Oct 21
Aelis Farma SA's (EPA:AELIS) 49% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Sep 06Some Confidence Is Lacking In Aelis Farma SA (EPA:AELIS) As Shares Slide 49%
Sep 06Shareholder Returns
| AELIS | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -6.0% | -5.6% | -0.06% |
| 1Y | -79.1% | -26.5% | -2.5% |
Return vs Industry: AELIS underperformed the French Biotechs industry which returned -28.2% over the past year.
Return vs Market: AELIS underperformed the French Market which returned -2.1% over the past year.
Price Volatility
| AELIS volatility | |
|---|---|
| AELIS Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.1% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: AELIS's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: AELIS's weekly volatility has increased from 9% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 26 | Pier Piazza | www.aelisfarma.com |
Aelis Farma SA, a clinical-stage biotechnology company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which is in phase I/II clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is headquartered in Bordeaux, France.
Aelis Farma SA Fundamentals Summary
| AELIS fundamental statistics | |
|---|---|
| Market cap | €38.13m |
| Earnings (TTM) | -€7.03m |
| Revenue (TTM) | €10.78m |
3.5x
P/S Ratio-5.4x
P/E RatioIs AELIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AELIS income statement (TTM) | |
|---|---|
| Revenue | €10.78m |
| Cost of Revenue | €0 |
| Gross Profit | €10.78m |
| Other Expenses | €17.81m |
| Earnings | -€7.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 100.00% |
| Net Profit Margin | -65.19% |
| Debt/Equity Ratio | 39.4% |
How did AELIS perform over the long term?
See historical performance and comparison